[Hormone replacement therapy following breast carcinoma]

Area of Science:

• Gynecology
• Oncology
• Endocrinology

Context:

• Hormone suppletion therapy (HST) is used for climacteric complaints.
• Women with treated breast cancer may benefit from HST, especially post-chemotherapy-induced early menopause.
• Existing pilot studies on HST and breast cancer recurrence lack robust methodology and sufficient sample size.

Purpose:

• To evaluate the potential benefits and risks of hormone suppletion therapy (HST) in women, particularly those with a history of breast cancer.
• To address the inconclusive evidence regarding the link between HST and breast cancer recurrence.

Summary:

• HST offers advantages such as decreased risks of cardiovascular disease and osteoporosis.
• A significant disadvantage of HST is the increased risk of developing breast cancer.
• Current research on HST's effect on breast cancer recurrence is methodologically limited and lacks adequate sample size, preventing definitive conclusions.

Impact:

• The findings underscore the need for caution when considering HST for breast cancer survivors.
• Further rigorous research is required to ascertain the safety of HST in this population.
• Until proven otherwise, the general recommendation advises against HST for patients with a history of treated breast carcinoma.